Cancer Research Institutions Challenge Federal Circuit’s Decision on Antibody Patent

The Dana-Farber Cancer Institute and Memorial Sloan-Kettering Cancer Center are collectively urging the Federal Circuit to reconsider its stance on a recent decision regarding Xencor’s patent application for an antibody. The centers assert that the ruling established an undesired precedent that could potentially impact future patents in a similar domain. For further details, the full context and implications of this ongoing legal challenge can be reviewed here.